



EUCAST

EUROPEAN COMMITTEE
ON ANTIMICROBIAL
SUSCEPTIBILITY TESTING


European Society of Clinical Microbiology and Infectious Diseases

Quality Assurance of antimicrobial susceptibility testing

Derek Brown

EUCAST Scientific Secretary


Trends in antimicrobial susceptibility testing guidelines (EARS-Net)



Quality Assurance


The total process by which the quality of laboratory reports can be guaranteed

Components of quality assurance



Components of quality assurance


Routine quality control



Routine quality control

Repeated testing of controls in parallel with tests to ensure that the test system is performing reproducibly within defined limits

Quality control of disk diffusion antimicrobial susceptibility tests



Specified routine quality control strains are used to monitor test performance

- Quality control strains may be purchased from culture collections or from commercial sources
- See EUCAST website for guidance on storage of control strains

EUCAST routine quality control strains

Organism	Culture collection numbers	Characteristics
<i>E. coli</i>	ATCC 25922; NCTC 12241; CIP 7624 DSM 1103; CCUG 17620, CECT 434	Susceptible, wild-type
<i>E. coli</i>	ATCC 35218; NCTC 11954, CIP 102181; DSM 5923, CCUG 30600; CECT 943	TEM-1 β -lactamase producer
<i>P. aeruginosa</i>	ATCC 27853; NCTC 12903; CIP 76110 DSM 1117; CCUG 17619; CECT 108	Susceptible, wild-type
<i>S. aureus</i>	ATCC 29213; NCTC 12973; CIP 103429 DSM 2569; CCUG 15915; CECT 794	Weak β -lactamase producer
<i>E. faecalis</i>	ATCC 29212; NCTC 12697; CIP 103214 DSM 2570; CCUG 9997; CECT 795	Susceptible, wild-type
<i>S. pneumoniae</i>	ATCC 49619; NCTC 12977; CIP 104340 DSM 11967; CCUG 33638	Penicillin intermediate
<i>H. influenzae</i>	ATCC 49766; NCTC 12975; CIP 103570; DSM 11970 CCUG 29539	Susceptible, wild-type
<i>Campylobacter jejuni</i>	ATCC 33560; NCTC 11351; CIP 702 DSM 4688; CCUG 11284	Susceptible, wild-type

EUCAST tables of target values and acceptable ranges for QC strains

http://www.eucast.org/ast_of_bacteria/qc_tables

Staphylococcus aureus ATCC 29213*


(NCTC 12973, CIP 103429, DSM 2569, CCUG 15915, CECT 794)

* β -lactamase-producing strain (weak)

Mueller-Hinton agar, McFarland 0.5, air, 35±1°C, 18±2h. Read zone edges as the point showing no growth from the back of the plate against a black background illuminated with reflected light.

Antimicrobial agent	MIC (mg/L)		Disk content (μ g)	Inhibition zone size (mm)	
	Target ¹	Range ²		Target ¹	Range ³
Amikacin	2	1-4	30	21	18-24
Ampicillin	-	-	2	18	15-21
Azithromycin	1	0.5-2	-	-	-
Benzylpenicillin	0.5-1	0.25-2	1 unit	15	12-18
Cefoxitin	2	1-4	30	27	24-30
Ceftaroline	0.25	0.125-0.5 ⁴	5	27	24-30
Ceftobiprole	0.25-0.5	0.125-1 ⁴	IP	IP	IP

Monitoring disk diffusion test performance



Response to disk diffusion QC results out of range

- Single test out of range – report susceptibility if no obvious problem.
- If two non-consecutive control zone diameters of 20 consecutive tests are out of range – then report results if no obvious problem but investigate.
- If two consecutive control zone diameters are outside the acceptable range – then investigate before reporting results. The tests may have to be repeated.
- If multiple agents (>2) are out of range on one day – then investigate before reporting results. The tests may have to be repeated.

EUCAST control strains for detection of resistance mechanisms

Quality control strains with defined resistance mechanisms may be used to confirm the ability to detect resistance. If resistance in a resistant control strain is not recognised suppress test results, retest and investigate.

Organism	Culture collection numbers	Characteristics
<i>K. pneumoniae</i>	ATCC 700603; NCTC 13368; CCUG 45421; CECT 7787	ESBL producer (SHV-18)
<i>S. aureus</i>	NCTC 12493	Oxacillin hetero-resistant, <i>mecA</i> positive
<i>E. faecalis</i>	ATCC 51299; NCTC 13379; CIP 104676; DSM 12956; CCUG 34289	High-level aminoglycoside resistant (HLAR) and vancomycin resistant (<i>vanB</i> positive)
<i>H. influenzae</i>	ATCC 49247; NCTC 12699; CIP 104604; DSM 9999; CCUG 26214	β -lactamase negative, ampicillin resistant (BLNAR)

EUCAST control strains for detection of resistance mechanisms (possible additional strains)

Organism	Characteristics
<i>S. pneumoniae</i>	Penicillin resistant (MIC 4 mg/L)
<i>E. coli</i>	Different ESBL phenotypes
<i>E. coli</i>	OXA-48
<i>E. coli</i>	Plasmid AmpC
<i>E. coli</i>	Carbapenemase producers
<i>K. pneumoniae</i>	KPC enzyme


Quality control by comparison of wild type with reference distributions from EUCAST website

Ampicillin / *Escherichia coli*

EUCAST zone diameter distribution - Reference database 2010-09-24

EUCAST disk diffusion method

Distributions include collated data from multiple sources, geographical areas and time periods and can never be used to infer rates of resistance



Disk content: 10

Epidemiological cut-off: WT ≥ 14 mm (MIC: ≤ 8 mg/L)



9053 observations (2 data sources)

Clinical breakpoints: S ≥ 14 mm, R < 14 mm

Sources of error in disk diffusion

Medium	Storage of plates
	Not prepared to instructions
	Batch to batch variation or change of supplier of agar
	Supplements (batch to batch variations, incorrect amount, expired)
	pH
	Agar depth/Agar volume
	Expiry date
Test conditions	“15-15-15”-rule not adhered to (suspension used within 15 min, disks applied within 15 min, incubation within 15 min)
	Incubation (temperature, atmosphere and time)
	Incorrect inoculation (too light, too heavy or uneven)
	Reading conditions, reading zone edges
Disks	Incorrect disk (wrong agent or wrong disk content)
	Disk potency (incorrect storage, disks not at room temperature when containers opened, labile agent, expiry date)
	Too many disks on plate (interference between agents)
Control organisms	Incorrect QC strain
	Mutation
	Contamination
	Age of culture

Quality control of MIC testing




- Use the recommended routine quality control strains to monitor test performance (see EUCAST QC tables).
- Test range must include the MIC of the control strain.

Quality control of MIC testing

Ertapenem / *Escherichia coli*

EUCAST MIC Distribution - Reference Database 2010-09-24

MIC distributions include collated data from multiple sources, geographical areas and time periods and can never be used to infer rates of resistance



MIC

Epidemiological cut-off: WT ≤ 0.064 mg/L

2181 observations (11 data sources)

Clinical breakpoints: S ≤ 0.5 mg/L, R > 1 mg/L

Quality control of MIC testing


- Use the recommended routine quality control strains to monitor test performance (see EUCAST QC tables).
- Test range must include the MIC of the control strain.
- Include a control without antimicrobial agent to ensure that the test strain grows adequately.
- Test the purity of inoculum by culture on solid medium to obtain isolated colonies (broth microdilution).
- If MIC of control is out of range the source of error must be sought and the test repeated.
- Check wild type distribution against EUCAST distribution on website.

Quality control by comparison of wild type with reference distributions from EUCAST website

Ertapenem / *Escherichia coli*

EUCAST MIC Distribution - Reference Database 2010-09-24

MIC distributions include collated data from multiple sources, geographical areas and time periods and can never be used to infer rates of resistance



MIC

Epidemiological cut-off: WT ≤ 0.064 mg/L

2181 observations (11 data sources)


Clinical breakpoints: S ≤ 0.5 mg/L, R > 1 mg/L

Quality control of automated systems




- Use the recommended routine quality control strains to monitor test performance (see manufacturer's instructions).
- Restricted range of test concentrations mean that the range may not include the MIC of the control strain.
- Purity of inoculum tested by culture on solid medium to obtain isolated colonies.
- If control is out of range the source of error must be sought and the test repeated.

Components of quality assurance



Components of quality assurance


External Quality Assessment (proficiency testing)



External Quality Assessment (EQA) (Proficiency testing)

The challenge of laboratory
procedures with specimens of
known but undisclosed content

The EQA process (UK NEQAS)



EQA report

- Reference MIC results
- Your results
- Scores highlighting your performance
- Cumulative score over time and mean for all laboratories
- Detailed results for laboratories using the same method as you
- Details of results with different guidelines
- Comments on particular problems

UK NEQAS for Antimicrobial Susceptibility		Laboratory	
Distribution: 1821		Page 1 of 10	
Dispatch date: 25-Oct-2004			
Intended Result	Year Report	Year Score	
Specimen 7240	Agar diffusion panel rifampicin susceptible chloramphenicol susceptible erythromycin susceptible chlorhexidine resistant bacitracin susceptible gentamicin susceptible neomycin susceptible kanamycin resistant streptomycin susceptible trimethoprim susceptible vancomycin susceptible miconazole susceptible	Agar diffusion panel susceptible susceptible susceptible resistant susceptible susceptible resistant susceptible susceptible susceptible susceptible susceptible	Year scored Year scored Year scored Year scored Year scored Year scored Year scored Year scored Year scored Year scored Year scored Year scored
Specimen 7241	Ex-herc-by coil ampicillin resistant cefazolin resistant cephalexin resistant cefuroxime resistant clindamycin resistant erythromycin resistant gentamicin susceptible kanamycin susceptible netilmicin susceptible pivmecillinam susceptible	Ex-herc-by coil resistant resistant resistant resistant resistant resistant susceptible susceptible susceptible susceptible susceptible	Year scored Year scored Year scored Year scored Year scored Year scored Year scored Year scored Year scored Year scored Year scored Year scored
Cumulative score information			
Total number of specimens sent to you for UK NEQAS for Antimicrobial Susceptibility over the last 6 distributions was 12			
Specimen numbers: 7047 7240 7241 7242 7243 7244 7245 7246 7247 7248 7249 7250 7251 7252 7253 7254 7255 7256 7257 7258 7259 7260			
Your cumulative score for the specimens contributed that you reported was 208 out of a possible 208			
This means your laboratory performed better than 99.9% of all laboratories using the same method as you (resistant was 199, 74 out of 208 possible out of 75)			
Your performance rating for UK NEQAS for Antimicrobial Susceptibility is A (the number of awarded scores for which your cumulative score has above or below the mean for UK laboratories is 1)			
Credited scores may change if participants' results are amended			
Comments			
The intended result for cefazolin (specimen 7240) is based on the consensus result in this was not tested in the reference laboratory. Please note when there is a difference in intended result between BSAC and NCSL guidelines for antimicrobials it is not being scored. Additional tests used by laboratories for confirmation e.g. MICs are also not scored.			
None of the linked methods are included in the 'see specified group under guideline followed'			
Enquiries			
Report specimens can be obtained by fax +44 (0)20 8205 1480 or email enquiries@ukneqas.org.uk			
Please do not give laboratory specimens, distribution material and cups, test specimens, antibiotics - email enquiries@ukneqas.org.uk			
Any technical enquiries related to this distribution, please contact Christine Tides using the email address above.			
Digital images of the results obtained in QAL with this distribution are available on our website www.ukneqas.org.uk			
Quality Assurance Laboratory An ISO 15189 Approved Centre for Reference UK NEQAS, Limited Luton, MK4 3LJ		© Copyright. The data in UK NEQAS reports are confidential. Participants must consent to the release of general findings from the website. Published on 27/10/04 by Tuesday, 26 January 2005 Phone: +44 (0)20 8205 1480 Fax: +44 (0)20 8205 1488	

EQA report

- Reference MIC results
- Your results
- Scores highlighting your performance
- Cumulative score over time and mean for all laboratories
- Details of results with different guidelines
- Detailed results for laboratories using the same method as you
- Comments on particular problems

UK NEQAS for Antimicrobial Susceptibility			Laboratory
Distribution : 1821		Page 1 of 10	
Dispatch date : 25-Oct-2004			
Intended Result	Year Report	Year Score	
Specimen 7240	Agar diffusion panel	Agar diffusion panel	
ampicillin	susceptible	susceptible	
chloramphenicol	susceptible	susceptible	
erythromycin	susceptible	susceptible	
colistin	not tested	not tested	
fosfomicin	not tested	not tested	
gentamicin	susceptible	susceptible	
kanamycin	not tested	not tested	
netilmicin	not tested	not tested	
penicillin	not tested	not tested	
streptomycin	not tested	not tested	
tetracycline	not tested	not tested	
vancomycin	not tested	not tested	
Specimen 7241	Escherichia coli	Escherichia coli	
ampicillin	not tested	not tested	
chloramphenicol	not tested	not tested	
erythromycin	not tested	not tested	
fosfomicin	not tested	not tested	
gentamicin	not tested	not tested	
kanamycin	not tested	not tested	
netilmicin	not tested	not tested	
penicillin	not tested	not tested	
streptomycin	not tested	not tested	
tetracycline	not tested	not tested	
vancomycin	not tested	not tested	
Cumulative score information			
Total number of specimens sent to you for UK NEQAS for Antimicrobial Susceptibility over the last 6 distributions was 12			
Specimen number: 7240 7246 7249 7251 7252 7253 7254 7255 7256 7257 7258 7259			
Your cumulative score for the specimens contributed that you reported was 200 out of a possible 200			
200 results were calculated from the reports received by UK laboratories using the specifications contributed by you recorded was 100.0%			
Your performance rating for UK NEQAS for Antimicrobial Susceptibility is A (the number of awarded scores for which your cumulative score has above or below the mean for UK laboratories is 1)			
Classified scores may change if participants' results are assessed			
Comments			
The intended result for colistin (specimen 7240) is based on the consensus result as this was not tested in the reference laboratory.			
Please note when there is a difference in intended result between BSAC and NCHS guidelines for interpretation it is not being scored. Additional tests used by laboratories for confirmation e.g. reflexive tests are not scored.			
Users of the linked method are included in the test specified group under guideline follow-up			
Enquiries			
Report enquiries can be obtained by fax +44 (0)20 8305 1480 or email enquiries@ukneqas.org.uk			
Please note that laboratory accreditation, distribution copyright and other test procedure numbers are used without consent.			
Any technical enquiries related to this distribution please contact Customer Help using the email address above.			
Digital images of the results obtained in QAL with this distribution are available on our website: www.ukneqas.org.uk			
Quality Assurance Laboratory An ISO 15189 Accredited Centre for Infection 41 Clarendon Road London SW4 7LJ Phone: +44 (0)20 8305 1480 Fax: +44 (0)20 8305 1488			
© Copyright. The data in UK NEQAS reports are confidential. Participants must consent to the release of report before printing data from the website. Published on 27/10/04 on Tuesday, 19 January 2005			

Evaluation


- Review the results with all staff (include successes and failures)
- Investigate problems
 - How many other participants had problems with the specimen?
 - Are there any comments on technical or interpretive issues?

Staphylococcus aureus

EARSNet specimen 2489 (VISA)

Antimicrobial agent	Reference MIC (mg/L)	EUCAST	CLSI
Penicillin	64	R	R
Cefoxitin	≥128	R	R
Oxacillin	≥128	R	R
Vancomycin	4	R	I
Teicoplanin	8-16	R	S/I
Erythromycin	≥128	R	R
Clindamycin	≥128	R	R
Gentamicin	128 – 256	R	R
Fusidic acid	0.06 - 0.12	S	-
Ciprofloxacin	16	R	R
Rifampicin	≥128	R	R
Tetracycline	64	R	R

Staphylococcus aureus specimen 2489



Staphylococcus aureus specimen 2489

Vancomycin resistance

MIC 4 mg/L

EUCAST resistant (breakpoints S \leq 2, R $>$ 2 mg/L)

CLSI intermediate (breakpoints S \leq 2, R \geq 16 mg/L)

- High error rate in reporting with all guidelines

Guideline	n	%S	%I	%R
EUCAST	655	45.8	2.4	51.8
CLSI	164	57.3	39.0	3.7

Staphylococcus aureus specimen 2489

Teicoplanin resistance

MIC 8-16 mg/L

EUCAST resistant (breakpoints S \leq 2, R $>$ 2 mg/L)

CLSI susceptible/intermediate (breakpoints S \leq 8, R \geq 32 mg/L)

- Reporting in line with guidelines

Guideline	n	%S	%I	%R
EUCAST	573	7.2	1.0	91.8
CLSI	147	47.0	43.5	9.5


Staphylococcus aureus specimen 2489

Vancomycin resistance

- No testing method was reliable
- Disk diffusion should not be used

Method	n	% reporting S
MIC	370	41.4
Automated	430	50.5
Disk diffusion only	16	87.5

Staphylococcus aureus (VISA) Gradient MIC test



Care needed in reading gradient tests

EQA conclusions

- Performance good for most organism-agent combinations
- Discrepancies more common when:
 - Susceptibility borderline
 - Critical differences between guidelines
 - Failure to follow guidelines
 - Specific technical issues
 - Guidelines permit variable reporting


Benefits of EQA in antimicrobial susceptibility testing

- Independent assessment of performance
- Assessment of performance over time
- Comparison with other laboratories
- Highlights problem areas
- Differences in guidelines highlighted
- Performance related to methods
- Education
- Performance indicator for accreditation

“Limitations” of EQA in antimicrobial susceptibility testing


- Number of specimens distributed is small
- May be considered inappropriate to send some organisms
- Specimens do not reflect routine isolates
- Laboratories may not treat specimens as routine

Components of quality assurance



Components of quality assurance

Internal Quality Assessment (specimen reprocessing)



Internal Quality Assessment (specimen reprocessing)

The challenge of laboratory procedures by repeat testing of specimens of unknown content

Internal quality assessment (IQA) process

- Specimens split and both processed on same day, or same specimen processed twice on the same day, with identification of repeat test blinded
- For susceptibility testing the same organism could be processed twice on the same day or repeated on different days
- Reports compared and discrepancies investigated
- Feedback
 - Rapid feedback of discrepancy reports
 - Frequent discussion and action in laboratory meetings

Problems highlighted by IQA at Addenbrooke's Hospital, Cambridge

- Variable susceptibility because different organisms picked from mixture on primary plates
- Wrong disk contents used e.g.
 - Ampicillin 10 µg instead of 2 µg for *H. influenzae*
- Borderline susceptibility leads to variable results e.g.
 - *S. aureus* erythromycin R changed to S
 - *S. aureus* mupirocin S changed to I
 - *S. aureus* fusidic acid S changed to R
- Discrepancies with “difficult” tests
 - Oxacillin with hetero-resistant MRSA
 - Vancomycin with VanB enterococcus
- Typographical errors

Benefits of IQA for antimicrobial susceptibility testing

- Tests reproducibility of all aspects of processing a specimen
- Covers areas not tested by EQA
- More samples than EQA
- locally responsive
- Rapid turnaround so problems investigated early
- Recognised by accreditation authorities

Limitations of IQA for antimicrobial susceptibility testing

- Discrepancies may not be related to susceptibility testing
- No reference results so the correct answer is unknown - both results could be wrong
- Cost

Quality assurance of antimicrobial susceptibility testing

- Multiple components contribute to maintaining the quality of antimicrobial susceptibility testing
- Quality assurance is essential to ensure reliable results